Literature DB >> 27189322

RECIST 1.1-Update and clarification: From the RECIST committee.

Lawrence H Schwartz1, Saskia Litière2, Elisabeth de Vries3, Robert Ford4, Stephen Gwyther5, Sumithra Mandrekar6, Lalitha Shankar7, Jan Bogaerts2, Alice Chen8, Janet Dancey9, Wendy Hayes10, F Stephen Hodi11, Otto S Hoekstra12, Erich P Huang13, Nancy Lin11, Yan Liu2, Patrick Therasse14, Jedd D Wolchok15, Lesley Seymour9.   

Abstract

The Response Evaluation Criteria in Solid Tumours (RECIST) were developed and published in 2000, based on the original World Health Organisation guidelines first published in 1981. In 2009, revisions were made (RECIST 1.1) incorporating major changes, including a reduction in the number of lesions to be assessed, a new measurement method to classify lymph nodes as pathologic or normal, the clarification of the requirement to confirm a complete response or partial response and new methodologies for more appropriate measurement of disease progression. The purpose of this paper was to summarise the questions posed and the clarifications provided as an update to the 2009 publication.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Clarifications; RECIST; Tumour response

Mesh:

Year:  2016        PMID: 27189322      PMCID: PMC5737828          DOI: 10.1016/j.ejca.2016.03.081

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009.

Authors:  Filip Janku; Donald A Berry; Jing Gong; Henrique A Parsons; David J Stewart; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2012-09-26       Impact factor: 12.531

3.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals.

Authors:  Binsheng Zhao; Yongqiang Tan; Daniel J Bell; Sarah E Marley; Pingzhen Guo; Helen Mann; Marietta L J Scott; Lawrence H Schwartz; Dana C Ghiorghiu
Journal:  Eur J Radiol       Date:  2013-03-13       Impact factor: 3.528

5.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

6.  The imaging viewpoint: how imaging affects determination of progression-free survival.

Authors:  Daniel Carl Sullivan; Lawrence H Schwartz; Binsheng Zhao
Journal:  Clin Cancer Res       Date:  2013-05-15       Impact factor: 12.531

  6 in total
  389 in total

1.  An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.

Authors:  Emerson Y Chen; Vikram Raghunathan; Vinay Prasad
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

2.  Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment.

Authors:  Ravi A Madan; Keith T Schmidt; Fatima Karzai; Cody J Peer; Lisa M Cordes; Cindy H Chau; Seth M Steinberg; Helen Owens; Joel Eisner; William R Moore; William L Dahut; James L Gulley; William D Figg
Journal:  Clin Genitourin Cancer       Date:  2020-03-29       Impact factor: 2.872

3.  Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.

Authors:  Jillian Phallen; Alessandro Leal; Brian D Woodward; Patrick M Forde; Jarushka Naidoo; Kristen A Marrone; Julie R Brahmer; Jacob Fiksel; Jamie E Medina; Stephen Cristiano; Doreen N Palsgrove; Christopher D Gocke; Daniel C Bruhm; Parissa Keshavarzian; Vilmos Adleff; Elizabeth Weihe; Valsamo Anagnostou; Robert B Scharpf; Victor E Velculescu; Hatim Husain
Journal:  Cancer Res       Date:  2018-12-20       Impact factor: 12.701

Review 4.  Translating preclinical MRI methods to clinical oncology.

Authors:  David A Hormuth; Anna G Sorace; John Virostko; Richard G Abramson; Zaver M Bhujwalla; Pedro Enriquez-Navas; Robert Gillies; John D Hazle; Ralph P Mason; C Chad Quarles; Jared A Weis; Jennifer G Whisenant; Junzhong Xu; Thomas E Yankeelov
Journal:  J Magn Reson Imaging       Date:  2019-03-29       Impact factor: 4.813

Review 5.  Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications.

Authors:  Kaustav Bera; Vamsidhar Velcheti; Anant Madabhushi
Journal:  Am Soc Clin Oncol Educ Book       Date:  2018-05-23

Review 6.  "How to" incorporate dual-energy imaging into a high volume abdominal imaging practice.

Authors:  Eric P Tamm; Ott Le; Xinming Liu; Rick R Layman; Dianna D Cody; Priya R Bhosale
Journal:  Abdom Radiol (NY)       Date:  2017-03

7.  Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients.

Authors:  William C Chen; Joe D Baal; Ulysis Baal; Jonathan Pai; Alexander Gottschalk; Lauren Boreta; Steve E Braunstein; David R Raleigh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-01-27       Impact factor: 7.038

8.  Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.

Authors:  Federico Carbone; Francesco Grossi; Aldo Bonaventura; Alessandra Vecchié; Silvia Minetti; Nicholas Bardi; Edoardo Elia; Anna Maria Ansaldo; Daniele Ferrara; Erika Rijavec; Maria Giovanna Dal Bello; Federica Biello; Giovanni Rossi; Marco Tagliamento; Angela Alama; Simona Coco; Paolo Spallarossa; Franco Dallegri; Carlo Genova; Fabrizio Montecucco
Journal:  Clin Exp Metastasis       Date:  2019-08-02       Impact factor: 5.150

9.  Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.

Authors:  Ashwathy Susan Mathew; Eshetu G Atenafu; Dawn Owen; Chris Maurino; Anthony Brade; James Brierley; Robert Dinniwell; John Kim; Charles Cho; Jolie Ringash; Rebecca Wong; Kyle Cuneo; Mary Feng; Theodore S Lawrence; Laura A Dawson
Journal:  Eur J Cancer       Date:  2020-05-24       Impact factor: 9.162

10.  Clinical and Radiologic Predictors of a Pathologic Complete Response to Neoadjuvant Chemotherapy (NACT) in Patients Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases: Results of a Prospective Multi-center Study.

Authors:  Aditi Bhatt; Pascal Rousset; Nazim Benzerdjeb; Praveen Kammar; Sanket Mehta; Loma Parikh; Gaurav Goswami; Sakina Shaikh; Vahan Kepenekian; Guillaume Passot; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2020-11-18       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.